• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一些含有喹喔啉二酮部分的新型二芳基脲衍生物的生物学评价、对接和分子动力学模拟

Biological evaluation, docking and molecular dynamic simulation of some novel diaryl urea derivatives bearing quinoxalindione moiety.

作者信息

Sadeghian-Rizi Sedighe, Khodarahmi Ghadamali Ali, Sakhteman Amirhossein, Jahanian-Najafabadi Ali, Rostami Mahboubeh, Mirzaei Mahmoud, Hassanzadeh Farshid

机构信息

Department of Medicinal Chemistry and Isfahan Pharmaceutical Sciences Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, I.R. Iran.

Department of Medicinal Chemistry, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, I.R. Iran.

出版信息

Res Pharm Sci. 2017 Dec;12(6):500-509. doi: 10.4103/1735-5362.217430.

DOI:10.4103/1735-5362.217430
PMID:29204178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5691576/
Abstract

In this study a series of diarylurea derivatives containing quinoxalindione group were biologically evaluated for their cytotoxic activities using MTT assay against MCF-7 and HepG2 cell lines. Antibacterial activities of these compounds were also evaluated by Microplate Alamar Blue Assay (MABA) against three Gram-negative (, and ), three Gram-positive (, and ) and one yeast-like fungus (Candida albicans) strain. Furthermore, molecular docking was carried out to study the binding pattern of the compounds to the active site of B-RAF kinase (PDB code: 1UWH). Molecular dynamics simulation was performed on the best ligand (16e) to investigate the ligand binding dynamics in the physiological environment. Cytotoxic evaluation revealed the most prominent cytotoxicity for 6 compounds with IC values of 10-18 μM against two mentioned cell lines. None of the synthesized compounds showed significant antimicrobial activity. The obtained results of the molecular docking study showed that all compounds fitted in the binding site of enzyme with binding energy range of -11.22 to -12.69 kcal/mol vs sorafenib binding energy -11.74 kcal/mol as the lead compound. Molecular dynamic simulation indicated that the binding of ligand (16e) was stable in the active site of B-RAF during the simulation.

摘要

在本研究中,使用MTT法对一系列含有喹喔啉二酮基团的二芳基脲衍生物针对MCF-7和HepG2细胞系进行了细胞毒性活性的生物学评估。还通过微孔板阿拉玛蓝法(MABA)对这些化合物针对三种革兰氏阴性菌(、和)、三种革兰氏阳性菌(、和)以及一种酵母样真菌(白色念珠菌)菌株的抗菌活性进行了评估。此外,进行了分子对接以研究这些化合物与B-RAF激酶活性位点(PDB代码:1UWH)的结合模式。对最佳配体(16e)进行了分子动力学模拟,以研究配体在生理环境中的结合动力学。细胞毒性评估显示,6种化合物对上述两种细胞系具有最显著的细胞毒性,IC值为10 - 18 μM。所有合成化合物均未表现出显著的抗菌活性。分子对接研究的结果表明,所有化合物均能与酶的结合位点契合,结合能范围为 - 11.22至 - 12.69 kcal/mol,而作为先导化合物的索拉非尼的结合能为 - 11.74 kcal/mol。分子动力学模拟表明,在模拟过程中配体(16e)在B-RAF的活性位点中的结合是稳定的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f5/5691576/807f91247f36/RPS-12-500-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f5/5691576/19c4baadffdf/RPS-12-500-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f5/5691576/c68e0f99414e/RPS-12-500-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f5/5691576/5f4dfa6d4efe/RPS-12-500-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f5/5691576/5e7320d40652/RPS-12-500-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f5/5691576/807f91247f36/RPS-12-500-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f5/5691576/19c4baadffdf/RPS-12-500-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f5/5691576/c68e0f99414e/RPS-12-500-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f5/5691576/5f4dfa6d4efe/RPS-12-500-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f5/5691576/5e7320d40652/RPS-12-500-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44f5/5691576/807f91247f36/RPS-12-500-g008.jpg

相似文献

1
Biological evaluation, docking and molecular dynamic simulation of some novel diaryl urea derivatives bearing quinoxalindione moiety.一些含有喹喔啉二酮部分的新型二芳基脲衍生物的生物学评价、对接和分子动力学模拟
Res Pharm Sci. 2017 Dec;12(6):500-509. doi: 10.4103/1735-5362.217430.
2
Synthesis, characterization, molecular docking studies and biological evaluation of some novel hybrids based on quinazolinone, benzofuran and imidazolium moieties as potential cytotoxic and antimicrobial agents.基于喹唑啉酮、苯并呋喃和咪唑鎓部分的一些新型杂化物作为潜在细胞毒性和抗菌剂的合成、表征、分子对接研究及生物学评价
Iran J Basic Med Sci. 2017 Sep;20(9):975-989. doi: 10.22038/IJBMS.2017.9260.
3
Biologically Active Heterocyclic Hybrids Based on Quinazolinone, Benzofuran and Imidazolium Moieties: Synthesis, Characterization, Cytotoxic and Antibacterial Evaluation.基于喹唑啉酮、苯并呋喃和咪唑鎓部分的生物活性杂环杂化物:合成、表征、细胞毒性和抗菌评估
Chem Biodivers. 2017 Apr;14(4). doi: 10.1002/cbdv.201600411. Epub 2017 Apr 3.
4
Docking study, synthesis and antimicrobial evaluation of some novel 4-anilinoquinazoline derivatives.一些新型4-苯胺基喹唑啉衍生物的对接研究、合成及抗菌活性评价
Res Pharm Sci. 2017 Oct;12(5):425-433. doi: 10.4103/1735-5362.213988.
5
Synthesis, antimicrobial evaluation and docking studies of some novel quinazolinone Schiff base derivatives.一些新型喹唑啉酮席夫碱衍生物的合成、抗菌评价及对接研究
Res Pharm Sci. 2018 Jun;13(3):213-221. doi: 10.4103/1735-5362.228942.
6
Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.2-氯-7-环戊基-7H-吡咯并[2,3-d]嘧啶衍生物抗乳腺癌的分子动力学与生物学评价
Comb Chem High Throughput Screen. 2017;20(8):703-712. doi: 10.2174/1386207320666170724110015.
7
Hybrid Pharmacophore Design, Molecular Docking, Synthesis, and Biological Evaluation of Novel Aldimine-Type Schiff Base Derivatives as Tubulin Polymerization Inhibitor.新型醛亚胺型席夫碱衍生物作为微管蛋白聚合抑制剂的杂合药效团设计、分子对接、合成及生物学评价
Chem Biodivers. 2018 Mar;15(3):e1700518. doi: 10.1002/cbdv.201700518. Epub 2018 Mar 7.
8
In silico and in vitro evaluation of newly synthesized pyrazolo-pyridine fused tetrazolo-pyrimidines derivatives as potential anticancer and antimicrobial agents.新合成的吡唑并吡啶稠合四唑并嘧啶衍生物作为潜在抗癌和抗菌剂的计算机模拟和体外评估
J Biomol Struct Dyn. 2025 Apr;43(7):3467-3490. doi: 10.1080/07391102.2023.2298731. Epub 2023 Dec 26.
9
Synthesis and characterization of some novel diaryl urea derivatives bearing quinoxalindione moiety.一些含喹喔啉二酮部分的新型二芳基脲衍生物的合成与表征
Res Pharm Sci. 2018 Feb;13(1):82-92. doi: 10.4103/1735-5362.220971.
10
Biological Activity, Apoptotic Induction and Cell Cycle Arrest of New Hydrazonoyl Halides Derivatives.新型酰腙卤代物的生物活性、诱导细胞凋亡和细胞周期阻滞。
Anticancer Agents Med Chem. 2019;19(9):1141-1149. doi: 10.2174/1871520619666190306123658.

引用本文的文献

1
Role of heterocycles in inhibition of VEGFR-2 - a recent update (2019-2022).杂环化合物在抑制血管内皮生长因子受体-2中的作用——最新进展(2019 - 2022年)
RSC Med Chem. 2023 Dec 12;15(2):416-432. doi: 10.1039/d3md00506b. eCollection 2024 Feb 21.
2
Research and development of ,'-diarylureas as anti-tumor agents.作为抗肿瘤药物的,'-二芳基脲的研发。 (注:原文中存在不明确的字符表述,可能影响准确理解,此翻译是按照给定原文尽量直译)
RSC Med Chem. 2023 May 9;14(7):1209-1226. doi: 10.1039/d3md00053b. eCollection 2023 Jul 20.
3
Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers.

本文引用的文献

1
Synthesis and characterization of some novel diaryl urea derivatives bearing quinoxalindione moiety.一些含喹喔啉二酮部分的新型二芳基脲衍生物的合成与表征
Res Pharm Sci. 2018 Feb;13(1):82-92. doi: 10.4103/1735-5362.220971.
2
A quantitative structure-activity relationship (QSAR) study of some diaryl urea derivatives of B-RAF inhibitors.一些B-RAF抑制剂的二芳基脲衍生物的定量构效关系(QSAR)研究。
Res Pharm Sci. 2016 Dec;11(6):445-453. doi: 10.4103/1735-5362.194869.
3
Linifanib--a multi-targeted receptor tyrosine kinase inhibitor and a low molecular weight gelator.
新型 3-甲基喹喔啉衍生物作为 VEGFR-2 抑制剂和凋亡诱导剂的设计、合成、对接、ADMET 研究和抗癌评估。
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1760-1782. doi: 10.1080/14756366.2021.1956488.
4
Charge-Transfer Complex of Linifanib with 2,3-dichloro-3,5-dicyano-1,4-benzoquinone: Synthesis, Spectroscopic Characterization, Computational Molecular Modelling and Application in the Development of Novel 96-microwell Spectrophotometric Assay.利尼伐尼与 2,3-二氯-3,5-二氰基-1,4-苯醌的电荷转移复合物:合成、光谱特征、计算分子建模及在新型 96 孔微量分光光度法测定中的应用。
Drug Des Devel Ther. 2021 Mar 12;15:1167-1180. doi: 10.2147/DDDT.S296502. eCollection 2021.
5
Exploring the interaction between epidermal growth factor receptor tyrosine kinase and some of the synthesized inhibitors using combination of and cytotoxicity methods.运用细胞毒性方法组合,探索表皮生长因子受体酪氨酸激酶与一些合成抑制剂之间的相互作用。
Res Pharm Sci. 2018 Dec;13(6):509-522. doi: 10.4103/1735-5362.245963.
利尼伐尼——一种多靶点受体酪氨酸激酶抑制剂和一种低分子量凝胶剂。
Chem Commun (Camb). 2015 Apr 14;51(29):6384-7. doi: 10.1039/c5cc00454c.
4
Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer.瑞戈非尼作为韩国难治性转移性结直肠癌患者的挽救治疗
Cancer Res Treat. 2015 Oct;47(4):790-5. doi: 10.4143/crt.2014.126. Epub 2014 Dec 2.
5
Regorafenib in gastrointestinal stromal tumors.瑞戈非尼用于胃肠道间质瘤
Future Oncol. 2014;10(9):1581-7. doi: 10.2217/fon.14.101.
6
g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations.g_mmpbsa——一种用于高通量MM-PBSA计算的GROMACS工具。
J Chem Inf Model. 2014 Jul 28;54(7):1951-62. doi: 10.1021/ci500020m. Epub 2014 Jun 19.
7
Tivozanib for the treatment of metastatic renal cancer.替沃扎尼布治疗转移性肾细胞癌。
Expert Rev Anticancer Ther. 2013 Jun;13(6):649-60. doi: 10.1586/era.13.40.
8
Synthesis of indazole based diarylurea derivatives and their antiproliferative activity against tumor cell lines.基于吲唑的二芳基脲衍生物的合成及其对肿瘤细胞系的抗增殖活性。
Bioorg Med Chem Lett. 2013 Apr 1;23(7):1989-92. doi: 10.1016/j.bmcl.2013.02.034. Epub 2013 Feb 15.
9
Tivozanib: current status and future directions in the treatment of solid tumors.替沃扎尼布:在实体瘤治疗中的现状和未来方向。
Expert Opin Investig Drugs. 2012 Dec;21(12):1851-9. doi: 10.1517/13543784.2012.733695. Epub 2012 Sep 26.
10
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma.Linifanib(ABT-869)治疗不可切除或转移性肝细胞癌的 II 期临床试验。
Cancer. 2013 Jan 15;119(2):380-7. doi: 10.1002/cncr.27758. Epub 2012 Jul 25.